Hypertension Management in Pre- and Post- Percutaneous Coronary Intervention - An Expert Opinion
Angiotensin receptor blockers (ARBs) are the most preferred antihypertensive agents among Indian cardiologists for managing hypertension in post-percutaneous coronary intervention (PCI) patients, an Indian expert opinion has revealed.
This first-of-its-kind expert opinion for managing hypertension in patients post PCI and with comorbidities has been published in the Journal of the Practice of Cardiovascular Sciences in April 2024.
336 non-interventional cardiologists and 256 interventional cardiologists participated in the expert opinion creation; which included a questionnaire on post-PCI management, followed by round table meetings.
Some key recommendations from the expert opinion include:
1) In monotherapy, ARBs were the most preferred antihypertensive agents for hypertension patients with different comorbidities*.
2) Metoprolol is the preferred choice among beta-blockers for post-PCI and heart failure patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.